Immune checkpoint inhibitor‐associated interstitial lung diseases correlate with better prognosis in patients with advanced non‐small‐cell lung cancer

BACKGROUND: Interstitial lung disease (ILD) induced by immune checkpoint inhibitors (ICIs) is a potentially life‐threatening adverse event. The purpose of this study was to evaluate whether the development of immune‐related adverse events (irAEs), especially ILD, was associated with treatment effica...

Descripción completa

Detalles Bibliográficos
Autores principales: Sugano, Teppei, Seike, Masahiro, Saito, Yoshinobu, Kashiwada, Takeru, Terasaki, Yasuhiro, Takano, Natsuki, Hisakane, Kakeru, Takahashi, Satoshi, Tanaka, Toru, Takeuchi, Susumu, Miyanaga, Akihiko, Minegishi, Yuji, Noro, Rintaro, Kubota, Kaoru, Gemma, Akihiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7113045/
https://www.ncbi.nlm.nih.gov/pubmed/32096610
http://dx.doi.org/10.1111/1759-7714.13364

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7113045/
https://www.ncbi.nlm.nih.gov/pubmed/32096610
http://dx.doi.org/10.1111/1759-7714.13364

Ejemplares similares